Skip to main content

Flow Cytometry Market to Surpass USD 6.99 Billion by 2031 | Skyquest Technology

Written by Customer Service on . Posted in Mergers And Acquisitions.

Westford USA, July 16, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the global flow cytometry market will attain a value of USD 6.99 Billion by 2031, with a CAGR of 7.17% during the forecast period (2024-2031). Flow cytometry has proliferated due to the COVID-19 outbreak. With its increased accuracy and higher throughput, this method offered an alternative method for COVID-19 testing and can help in avoiding any limitations posed by the existing PCR or antibody-based options. The segment has thus grown due to flow cytometry techniques in COVID-19 diagnosis and disease tracking. The fact that new products are also being introduced into this realm goes on to prove that the pandemic has stirred advances in flow cytometry.

Download a detailed overview:

https://www.skyquestt.com/sample-request/flow-cytometry-market

Browse in-depth TOC on “Flow Cytometry Market”

  • Pages – 157
  • Tables – 130
  • Figures – 77

Flow cytometry Market Overview:

Report Coverage Details
Market Revenue in 2023 USD 4.25 Billion
Estimated Value by 2031 USD 6.99 Billion
Growth Rate Poised to grow at a CAGR of 7.17%
Forecast Period 2024–2031
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Technology, Product & Services, Application, End User, and Region
Geographies Covered North America, Europe, Asia-Pacific, Middle East & Africa, Latin America
Report Highlights Updated financial information / product portfolio of players
Key Market Opportunities Increase In Government Funding for Clinical Studies Related to In-Vitro Molecular Diagnostics
Key Market Drivers Rising Demand for Personalized Medicine Drives Flow Cytometry Market

Media & Entertainment has the Largest Market Due to Increase in Subscription-Based Streaming Services

Media & entertainment segment ranked top among all other segments in terms of adoption in the year 2023. This is majorly due to the huge surge in the consumption of subscription- based services and the trends of streaming of content. Users are satisfied with flow cytometry when it comes to streaming, downloads, and in-application purchases on platforms like Netflix, Spotify and others. Moreover, the inclusion of secure payment gateways in over-the-top gaming and digital media platforms has taken this dominance to the next level.

Software Segment Expected to have the Fastest Growth by Providing Statistical Advice

The software segment is likely to acquire a higher growth rate from 2024-2031. Software plays a major role in processing, acquiring data from cytometers for analyzing the given information, and providing statistical advice. A diverse list of applications creates great expectations regarding the future market trends in the near years. Also, the launch of new products in the market by some of the leading companies is expected to drive this segment in the future.  

Extensive R&D Activities Enable North America to Hold the Largest Market Share

North American region accounted for the largest market share in 2023, due to well-established infrastructure of the health care and pharmaceutical sector as well as rapid rise in the health care expenditure in developed nation like the U.S, which would boost the demand in clinical and researcher application of flow cytometry. Hence, huge advancements in therapeutic procedures and consistent improvements in public as well as private investments lodged by prominent market stakeholders in cancer research have significantly cemented the need for such instruments even more in this region.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/flow-cytometry-market

Flow Cytometry Market Insights:

Drivers

  • Advancements and Demand in Flow Cytometry
  • Rising Demand for Personalized Medicine Drives Flow Cytometry Market
  • Increasing Incidences of Chronic Diseases

Restraints

  • High Costs Impede Flow Cytometry Adoption in Developing Economies
  • Limited Accessibility in Resource-Poor Settings
  • Competition From Emerging Technologies as well as Established Methods

Prominent Players in Flow Cytometry Market

The following are the Top  Flow Cytometry Companies

  • Becton, Dickinson, and Company
  • Danaher Corporation
  • Thermo Fisher Scientific, Inc.
  • Luminex Corporation
  • Agilent Technologies, Inc.
  • Sony Group Corporation
  • Bio-Rad Laboratories, Inc.
  • Miltenyi Biotec GmbH
  • Enzo Biochem, Inc.
  • Sysmex Corporation

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/flow-cytometry-market

Key Questions Answered in Flow cytometry Market Report

  • What is the projected market value of the Flow Cytometry Market?
  • What are the key market trends in the Flow Cytometry Market?
  • Which is the leading region Flow Cytometry Market in the world and why?

This report provides the following insights:

  • Analysis of key drivers (growing demand for better data security, rising adoption of Blockchain and IoT technologies, increasing use of decentralized systems in different industry verticals), restraints (interoperability issues with legacy systems, complexities in integration with existing infrastructure, concerns regarding scalability of gas cleaning technologies systems), and opportunities (growing demand for data monetization, rising demand for transparent yet trusted transactions), influencing the growth of flow cytometry  market.
  • Market Penetration: All-inclusive analysis of product portfolio of different market players and status of new product launches.
  • Product Development/Innovation: Elaborate assessment of R&D activities, new product development, and upcoming trends of the flow cytometry market.
  • Market Development: Detailed analysis of potential regions where the market has potential to grow.
  • Market Diversification: Comprehensive assessment of new product launches, recent developments, and emerging regional markets.
  • Competitive Landscape: Detailed analysis of growth strategies, revenue analysis, and product innovation by new and established market players.

Related Reports:

Monoclonal Antibodies Market

Tissue Sectioning Market

CNS (Central Nervous System) Therapeutics Market

Circulating Tumor Cell Market 

Carcinoembryonic Antigen Market 

About Us:

SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.

We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.

Contact:

Mr. Jagraj Singh

Skyquest Technology

1 Apache Way,

Westford,

Massachusetts 01886

USA (+1) 351-333-4748

Email: sales@skyquestt.com

Visit Our Website: https://www.skyquestt.com/

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.